Riskpilot← Back to searchSign inGet full accessOctapeptide AB
ABActiveOrg 5567197586Richertsgatan 16Research and experimental development on natural sciences and engineering · NACE 7210Est. 20070 employees
Revenue 2025
SEK 0
EBITDA margin
—
-31% vs 2024
Equity ratio
96.9%
Financial strength
Net profit 2025
SEK -10K
-102% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -10K | -31% |
| Net profit | SEK -10K | -102% |
| Total assets | SEK 546K | +0% |
| Equity | SEK 529K | -2% |
| Employees | 0 | — |
Legal name
Octapeptide AB
Org number
5567197586
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
9 januari 2007
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Ljungblad, Britt Inger
Company purpose
Aktiebolaget ska bedriva utveckling av läkemedel, konsultverksam- het i hälso- och sjukvård och därmed liknande verksamhet. Bolaget skall även bedriva fastighetsförvaltning.
Address
Richertsgatan 16
Email
fam.ljungblad@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −10 | −1 | −5 | −8 | −10 |
| Depreciation & amort. | −0 | −0 | — | −0 | — |
| EBIT | −10 | −1 | −5 | −8 | −10 |
| Net financials | — | — | −469 | 470 | 0 |
| Profit before tax | −10 | −1 | −473 | 462 | −10 |
| Tax | −0 | −0 | — | −0 | — |
| Net profit | −10 | −1 | −473 | 462 | −10 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 572 | 551 | 78 | 547 | 546 |
| Equity | 262 | 261 | 78 | 540 | 529 |
| Long-term debt | 290 | 290 | 0 | 8 | 17 |
| Short-term debt | 19 | 0 | — | 0 | — |
| Total debt | 309 | 290 | 0 | 8 | 17 |
EBITDA margin
-1047800.0%
This company
15.8%
Market median
-6631746% vs market
20212025
Equity ratio
96.9%
This company
38.2%
Market median
+154% vs market
20212025
Return on equity
-1.9%
This company
18.4%
Market median
-110% vs market
20212025
Net profit margin
-1009600.0%
This company
8.1%
Market median
-12464298% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.03×
This company
0.62×
Market median
+95% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2022 | |
| Chairman | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Octapeptide AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl Johan Ljungblad | Board of Directors | 0 companies |
| Britt Inger Ljungblad | Chairman | 0 companies |
| Emma Cecilia Björk | Board of Directors | 0 companies |